Published in Eur J Immunol on October 01, 2007
MicroRNA miR-155 inhibits bone morphogenetic protein (BMP) signaling and BMP-mediated Epstein-Barr virus reactivation. J Virol (2010) 1.23
Synergistic effect of TGF-beta superfamily members on the induction of Foxp3+ Treg. Eur J Immunol (2010) 1.13
Loss of endogenous bone morphogenetic protein-6 aggravates renal fibrosis. Am J Pathol (2011) 1.03
Effect of bone morphogenetic protein-6 on macrophages. Immunology (2008) 0.95
Induction of interleukin-6 expression by bone morphogenetic protein-6 in macrophages requires both SMAD and p38 signaling pathways. J Biol Chem (2010) 0.90
Bone morphogenetic protein-6 induces the expression of inducible nitric oxide synthase in macrophages. Immunology (2009) 0.88
HEY1 Leu94Met gene polymorphism dramatically modifies its biological functions. Oncogene (2009) 0.87
Exogenous heparin binds and inhibits bone morphogenetic protein 6 biological activity. Int Orthop (2013) 0.80
The BMP Pathway Participates in Human Naive CD4+ T Cell Activation and Homeostasis. PLoS One (2015) 0.80
Transcriptional responses of cultured rat sympathetic neurons during BMP-7-induced dendritic growth. PLoS One (2011) 0.80
The immunological contribution to heterotopic ossification disorders. Curr Osteoporos Rep (2015) 0.76
Modulation of bone morphogenic protein signaling in T-cells for cancer immunotherapy. J Immunotoxicol (2013) 0.75
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med (2002) 24.07
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med (2004) 12.20
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature (2010) 8.78
Oncogenically active MYD88 mutations in human lymphoma. Nature (2010) 7.34
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science (2008) 6.52
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell (2003) 6.11
Molecular diagnosis of Burkitt's lymphoma. N Engl J Med (2006) 6.10
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med (2003) 6.06
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A (2008) 5.90
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature (2012) 4.33
Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell (2010) 3.37
Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood (2005) 3.12
Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell (2010) 2.43
B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. Proc Natl Acad Sci U S A (2010) 2.10
Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med (2007) 1.94
Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood (2013) 1.86
Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood (2009) 1.81
A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients. Blood (2009) 1.74
Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood (2014) 1.71
Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms. Cancer Discov (2014) 1.70
Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood (2007) 1.60
Characterization of early stages of human B cell development by gene expression profiling. J Immunol (2007) 1.60
Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Blood (2011) 1.41
[Leadership and academic competence]. Tidsskr Nor Laegeforen (2010) 1.37
Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin Cancer Res (2011) 1.18
EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood (2013) 1.17
BMP-6 inhibits growth of mature human B cells; induction of Smad phosphorylation and upregulation of Id1. BMC Immunol (2005) 1.02
NY-ESO-1 protein expression and humoral immune responses in prostate cancer. Prostate (2004) 1.00
Expression of the adult intestinal stem cell marker Lgr5 in the metastatic cascade of colorectal cancer. Int J Clin Exp Pathol (2011) 0.99
Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones. Blood (2010) 0.98
Serological cloning of cancer/testis antigens expressed in prostate cancer using cDNA phage surface display. Cancer Immunol Immunother (2004) 0.96
Activation of phosphatidylinositol 3-kinase is important for erythropoietin-induced erythropoiesis from CD34(+) hematopoietic progenitor cells. Exp Hematol (2002) 0.94
Wnt3A activates canonical Wnt signalling in acute lymphoblastic leukaemia (ALL) cells and inhibits the proliferation of B-ALL cell lines. Br J Haematol (2006) 0.93
BMP-6 inhibits human bone marrow B lymphopoiesis--upregulation of Id1 and Id3. Exp Hematol (2006) 0.93
Palliative pelvic radiotherapy of symptomatic incurable rectal cancer - a systematic review. Acta Oncol (2013) 0.91
Role of Smad proteins in resistance to BMP-induced growth inhibition in B-cell lymphoma. PLoS One (2012) 0.91
The amount of DNA damage needed to activate the radiation-induced G2 checkpoint varies between single cells. Radiother Oncol (2011) 0.90
Cloning, pharmacological characterisation and tissue distribution of a novel 5-HT4 receptor splice variant, 5-HT4(i). Naunyn Schmiedebergs Arch Pharmacol (2004) 0.90
LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome. Haematologica (2011) 0.90
TGF-β-induced growth inhibition in B-cell lymphoma correlates with Smad1/5 signalling and constitutively active p38 MAPK. BMC Immunol (2010) 0.87
Bone marrow stroma cells regulate TIEG1 expression in acute lymphoblastic leukemia cells: role of TGFbeta/BMP-6 and TIEG1 in chemotherapy escape. Int J Cancer (2008) 0.86
SARA is dispensable for functional TGF-β signaling. FEBS Lett (2012) 0.84
Single nucleotide polymorphisms of the adult intestinal stem cell marker Lgr5 in primary and metastatic colorectal cancer. Am J Transl Res (2012) 0.84
CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas. Hum Pathol (2009) 0.83
Bone morphogenetic proteins inhibit CD40L/IL-21-induced Ig production in human B cells: differential effects of BMP-6 and BMP-7. Eur J Immunol (2011) 0.82
Influence of polymorphisms in genes encoding immunoregulatory proteins and metabolizing enzymes on susceptibility and outcome in patients with diffuse large B-cell lymphoma treated with rituximab. Leuk Lymphoma (2013) 0.82
Polymorphisms in genes encoding interleukin-10 and drug metabolizing enzymes GSTP1, GSTT1, GSTA1 and UGT1A1 influence risk and outcome in Hodgkin lymphoma. Leuk Lymphoma (2012) 0.82
Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times. Br J Haematol (2011) 0.82
FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab. BMC Cancer (2014) 0.82
Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma. BMC Cancer (2012) 0.82
Effect of cycloheximide on epidermal growth factor receptor trafficking and signaling. FEBS Lett (2012) 0.81
Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study. BMC Cancer (2012) 0.81
Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma. Leuk Lymphoma (2014) 0.78
Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma. Blood (2013) 0.78
Identification of highly methylated genes across various types of B-cell non-hodgkin lymphoma. PLoS One (2013) 0.77
Analysis of the autoantibody repertoire in Burkitt's lymphoma patients: frequent response against the transcription factor ATF-2. Cancer Immunol Immunother (2004) 0.77
Patient reported outcomes of symptoms and quality of life among cancer patients treated with palliative pelvic radiation: a pilot study. BMC Res Notes (2011) 0.77
Signaling pathways in lymphoma: pathogenesis and therapeutic targets. Future Oncol (2013) 0.77
High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era. Leuk Lymphoma (2014) 0.77
Altered BCR and CD40 signalling are associated with clinical outcome in small lymphocytic lymphoma/chronic lymphocytic leukaemia and marginal zone lymphoma patients. Br J Haematol (2012) 0.76
[Close cooperation, but not oversteering]. Tidsskr Nor Laegeforen (2010) 0.75
Experiences of Patients With Breast Cancer of Participating in a Lifestyle Intervention Study While Receiving Adjuvant Chemotherapy. Cancer Nurs (2017) 0.75
Spiritual Well-being in Patients With Metastatic Colorectal Cancer Receiving Noncurative Chemotherapy: A Qualitative Study. Cancer Nurs (2016) 0.75
Karyotyping of diffuse large B-cell lymphomas: loss of 17p is associated with poor patient outcome. Eur J Haematol (2013) 0.75
Palliative Cancer Patients' Experiences of Participating in a Lifestyle Intervention Study While Receiving Chemotherapy. Cancer Nurs (2015) 0.75
[Molecular diagnosis of malignant lymphomas]. Tidsskr Nor Laegeforen (2009) 0.75